Composition for improving quality of sleep
A composition containing 8-HEPE or a Krilliata extract enhances sleep quality by reducing light sleep and increasing deep and REM sleep, addressing the lack of effective sleep quality improving compositions.
Patent Information
- Application Number
- JP2023077388
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-09
- Publication Date
- 2024-11-21
AI Technical Summary
There is a need for compositions that improve sleep quality, as existing sleep quality improving compositions containing 8-hydroxyeicosapentaenoic acid (8-HEPE) and/or krill-derived ingredients are lacking.
A composition containing 8-hydroxyeicosapentaenoic acid (8-HEPE) or an organic solvent extract of an organism of the order Krilliata, such as Euphausia pacifica, is used to enhance sleep quality by reducing light sleep and increasing deep and REM sleep.
The composition effectively decreases the proportion of light sleep and increases the proportion of deep and REM sleep, thereby improving sleep quality and potentially alleviating anxiety, tension, and depression, and reducing daytime sleepiness.
Smart Images

Figure 2024162135000001 
Figure 2024162135000002 
Figure 2024162135000003
Abstract
Description
[Technical field]
[0001] The present invention relates to methods and compositions for improving sleep quality. [Background technology]
[0002] The physiological functions of derivatives of highly unsaturated fatty acids (e.g., metabolites such as oxides) have been attracting attention. For example, 8-hydroxyeicosapentaenoic acid (8-HEPE) is a derivative produced by oxidation (hydroxylation) of the 8-position carbon of eicosapentaenoic acid (EPA), and 8-HEPE has a higher peroxisome proliferator-activated receptor (PPAR) activation effect than EPA, and is a compound that is expected to have preventive and ameliorative effects on metabolic diseases such as obesity and diabetes (Non-Patent Document 1). 8-HEPE does not exist in large amounts in nature; for example, Isada (Euphausia pacifica) contains only a few tens of ppm of 8-HEPE (Non-Patent Document 2). In addition to 8-HEPE, Isada also contains several ppm of 8-hydroxyeicosatetraenoic acid (8-HETE), in which a hydroxyl group has been introduced at the 8th position of arachidonic acid, and 10-hydroxydocosahexaenoic acid (10-HDoHE), in which a hydroxyl group has been introduced at the 10th position of docosahexaenoic acid (DHA). These derivatives are also expected to be used as new functional ingredients and pharmaceuticals (Non-Patent Documents 3 and 4).
[0003] 8-HEPE strongly activates peroxisome proliferator-activated receptor α (PPARα) (Non-Patent Documents 5-6). It is known that activation of PPARα regulates the expression of clock genes (Non-Patent Document 7). However, there have been no reports that 8-HEPE or an extract derived from Isada containing 8-HEPE improves sleep quality. In fact, to the knowledge of the present inventors, no composition that improves sleep quality containing 8-HEPE and / or a component derived from krill existed prior to the filing date of this application.
[0004] Therefore, there is a need for compositions that improve sleep quality.
[0005] The prior art literature related to the invention of this application includes the following: [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Yamada H et al., Journal of Lipid Research,55,895-904,2014 [Non-Patent Document 2] Yamada H et al., Scientific Reports, 7, 9944, 2017 [Non-Patent Document 3] Klawitter J et al., J Lipid Res.2014Jun;55(6):1139-49. [Non-Patent Document 4] Hashimoto M et al. Biochim Biophys Acta.2015Feb;1851(2):203-9 [Non-Patent Document 5] Yamada et al., Journal of Lipid Research.2014 [Non-Patent Document 6] Yamada et al., Journal of Lipids 2016 [Non-Patent Document 7] Shirai et al., BBRC.2007 Summary of the Invention [Problem to be solved by the invention]
[0007] The problem to be solved by the present invention is to provide compositions and methods for improving sleep quality. [Means for solving the problem]
[0008] The inventors have demonstrated that sleep quality can be improved by a composition containing 8-hydroxyeicosapentaenoic acid (8-HEPE) or a composition containing an organic solvent extract of an euphausiidae organism or a dried product thereof, thereby solving the above-mentioned problem.
[0009] For example, the present invention provides the following: (Item 1) A composition for improving sleep quality, comprising an oil component of an organism of the superorder Polypodidae, a solid component obtained by drying the oil component, an organic solvent extract of an organism of the superorder Polypodidae, a solid component obtained by drying the dried matter of the organic solvent extract, and a substance selected from the group consisting of 8-hydroxyeicosapentaenoic acid (8-HEPE). (Item 2) 2. The composition according to item 1, wherein the organism of the superorder Euphausiidae is an organism of the order Euphausiidae. (Item 3) 3. The composition according to item 2, wherein the organism of the order Euphausiidae is selected from the group consisting of Euphausia pacifica, Euphausia superba, and combinations thereof. (Item 4) 4. The composition according to item 3, wherein the organism of the order Euphausiidae is Euphausia pacifica. (Item 5) 2. The composition according to item 1, wherein the oil component is a treatment liquid obtained by enzymatically treating a ground product of the organism suspended in an aqueous solution with a protease under a condition of pH 3 to 4. (Item 6) 6. The composition according to item 5, wherein the protease is a protease derived from Aspergillus oryzae. (Item 7) 2. The composition according to claim 1, wherein the solid component is a powder. (Item 8) Item 2. The composition according to item 1, wherein the organic solvent extract is an extract prepared using a solvent selected from the group consisting of ethyl alcohol, acetone, and hexane. (Item 9) 2. The composition of claim 1, wherein the improvement in sleep quality is selected from the group consisting of a decrease in the proportion of light sleep time in total sleep time, an increase in the proportion of deep sleep time in total sleep time, and a combination thereof. (Item 10) 2. The composition according to item 1, which is a dietary composition or a pharmaceutical composition. Effect of the Invention
[0010] The composition provided by the present invention improves sleep quality. In particular, it has been demonstrated that the excellent effect of decreasing the proportion of light sleep and increasing the proportion of REM sleep and deep sleep in subjects in their 60s is demonstrated. Furthermore, the present invention is expected to improve QOL and prevent mental and physical disorders caused by poor sleep quality by improving sleep quality. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The present invention will be described below. Throughout this specification, the singular expression should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense that they are commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this invention belongs. In case of conflict, this specification (including definitions) shall prevail.
[0012] (Definition of terms) Listed below are definitions of terms specifically used in this specification.
[0013] The term "improvement of sleep quality" as used herein includes any element related to improvement of sleep quality, such as elimination and / or reduction of dissatisfaction in subjects who are temporarily dissatisfied with sleep. Indicators of "improvement of sleep quality" include, for example, a reduction in the proportion of light sleep time in total sleep time, an increase in the proportion of deep sleep and / or REM sleep time in total sleep time, and combinations thereof. Alternatively, indicators of "improvement of sleep quality" include, as secondary indicators, relief of anxiety, tension, and depression in subjects who are temporarily low in vitality and energy, temporary improvement in vitality and energy, and reduction of daytime sleepiness.
[0014] To measure the quality of sleep, polysomnography (PSG) and a small electroencephalograph (sleep scope) can be used. In addition, as an index of QOL measurement based on the quality of sleep, for example, a mood state evaluation can be used (for example, the Profile of Mood States 2nd Edition (POMS2) for adults, a shortened version, can be used as a subjective evaluation).
[0015] As used herein, the term "composition containing an active ingredient" refers to a composition obtained by manipulating a starting material (e.g., including but not limited to, extraction, drying, etc.), and includes, but is not limited to, an extract that contains any ingredient that contributes to improving sleep quality.
[0016] The term "active ingredient" as used in this specification is a concept that encompasses any ingredient in the above-mentioned "composition containing an active ingredient" that contributes to improving sleep quality, as well as 8-hydroxyeicosapentaenoic acid (8-HEPE).
[0017] As used herein, the term "total sleep time" refers to the time from falling asleep to waking up.
[0018] As used herein, the term "light sleep" refers to non-REM (NREM) stage 1 and 2 sleep, characterized by little eye movement and reduced physical activity.
[0019] As used herein, the term "deep sleep" refers to non-REM stages 3 and 4, or slow-wave sleep (SWS), a state of relaxation characterized by decreased body temperature and blood pressure. During deep sleep, repair and recovery occur in the body, metabolism slows, and growth hormone is secreted.
[0020] (Sleep quality measurement) In the sleep quality evaluation of this clinical trial, electroencephalograms were used as an objective index of sleep quality. The gold standard for sleep evaluation is polysomnography (PSG), but since it is performed in an overnight hospitalization environment, it is economically and time-consuming. Therefore, in the present invention, evaluation was performed using a small electroencephalograph called Sleep Scope, which is certified as a medical device. The performance of Sleep Scope to acquire EEG was verified, and it was confirmed that it covers the frequency band required for sleep stage judgment and can acquire characteristic waveforms essential for sleep stage judgment. In the analysis program, the function of judging sleep stages was also verified in accordance with the standards of the American Academy of Sleep Medicine. As a result, it has been reported that it is possible to judge sleep stages based on EEG acquired by Sleep Scope (Masaki Yoshida et al., Performance Verification of a Portable 1-Channel Electroencephalograph, Sleep Oral Medicine, 2015;1,140-147). The Pittsburgh Sleep Quality Index Japanese version (PSQI-J) can be used as an index of subjective sleep quality. The PSQI-J involves answering a total of 18 questions, and the answers are classified into seven components (sleep quality, sleep duration, time to fall asleep, sleep efficiency, difficulty sleeping, use of sleeping pills, and daytime sleepiness) and scored (Uchiyama Makoto, Rating Scale. Guidelines for Managing and Treating Sleep Disorders, 3rd Edition, Jiho Co., Ltd.). It is also featured in the Clinical Sleep Testing Manual (edited by the Japanese Society of Sleep Research, Supplementary Tests for Diagnosing Sleep Disorders, Revised Clinical Sleep Testing Manual, Life Science Co., Ltd.), and is a questionnaire that is widely used to evaluate sleep quality.
[0021] In this clinical trial, the Profile of Mood States 2nd Edition (POMS2) for adults was used as a subjective assessment for the mood state evaluation. POMS2 is composed of seven scales, anger-hostility, confusion-embarrassment, depression-depression, fatigue-apathy, tension-anxiety, vigor-vitality, and friendliness, as well as an overall mood state that comprehensively represents negative mood states, and is thought to be able to grasp mood states more multifacetedly (Heuchert et al., POMS2 Japanese Version Manual, Kaneko Shobo).
[0022] (Improvement of sleep quality) In one embodiment, the method has the effect of reducing sleepiness and fatigue upon awakening in healthy subjects who are temporarily dissatisfied with their sleep, and by reducing light sleep and increasing the proportion of deep sleep and REM sleep, it can have the effect of improving sleep quality.
[0023] The Ministry of Health, Labor and Welfare's "Health Japan 21" includes "rest and mental health" as one of the lifestyle issues that lead to lifestyle-related diseases and lifestyle-related diseases. The importance of getting better sleep has been raised, with the "Sleep Guidelines for Health Promotion - 7 Points for Comfortable Sleep" established in 2003 and the "Sleep Guidelines for Health Promotion 2014 - 12 Points for Sleep" established in 2014 as a central issue in rest and mental health promotion. In fact, one in five Japanese people are dissatisfied with the quality of their sleep, such as "difficulty falling asleep" or "waking up in the middle of the night," and the Japanese people have the shortest sleep time among developed countries (Ministry of Health, Labor and Welfare, Sleep Guidelines for Health Promotion, 2014, March 2014) (Organization for Economic Co-operation and Development. Society at a Glance 2009; OECD Social Indicators, 2009). Human sleep consists of REM sleep and non-REM sleep, and according to the American Academy of Sleep Medicine (AASM) classification method, non-REM sleep is classified into light sleep (stage N1, stage N2) and deep sleep (stage N3) (Keisuke Suzuki, Objective Testing of Sleep and Wakefulness, Journal of Clinical Physiology, 2019;49,83-87). It has been reported that the proportion of each of these sleep stages decreases with age, and light sleep increases with deep sleep and REM sleep, resulting in a deterioration in sleep quality (Li et al., Age and gender differences in objective sleep properties using large-scale body acceleration data in a Japanese population. Scientific reports 2021;11:9970) (Matthew Walker, Sleep is the Best Solution, Chapter 5 Age and Sleep, SB Creative). It is thought that increasing deep sleep and REM sleep improves sleep quality. "The function of improving sleep quality by increasing the proportion of deep sleep and REM sleep" can be judged to correspond to the maintenance and promotion of health in healthy individuals.
[0024] (Effects related to improved sleep quality) A function that helps relieve anxiety, tension, and depression in people who experience occasional drops in vitality and energy, and helps temporarily improve vitality and energy and reduce daytime sleepiness. In "Health Japan 21," mental health is described as "an important condition for living a lively and true to oneself" and "has a great impact on the quality of life." It is important for mental health to recover from mental disorders and return to a state of vitality (Ministry of Health, Labor and Welfare, Health Japan 21 (Rest and Mental Health) 3. Rest and Mental Health). "Helps relieve anxiety, tension, and depression in people who are temporarily low in vitality and energy, and helps to temporarily improve vitality and energy and reduce daytime sleepiness" was determined to be in line with maintaining and promoting the health of healthy people. Furthermore, the results of the 2019 National Health and Nutrition Survey reported that the percentage of people who felt sleepy during the day three or more times a week exceeded 30% of men and women aged 20 years or older, regardless of the amount of sleep they received (Ministry of Health, Labor and Welfare, Summary of the Results of the 2019 National Health and Nutrition Survey). "The function of reducing daytime sleepiness" was also determined to be in line with maintaining and promoting the health of healthy people.
[0025] (Active ingredient of the present invention) The active ingredient of the composition of the present invention can be typically prepared using Euphausia pacifica (also called Euphausia pacifica) as a starting material. The starting material is not limited thereto, and organisms belonging to the order Euphausiidae, for example, Antarctic krill (Euphausia superba) can also be used. Furthermore, the source of the active ingredient of the present invention is not limited to organisms belonging to the order Euphausiidae, and for example, organisms belonging to the superorder Euphausiidae can also be used as a source of the active ingredient of the present invention. Alternatively, 8-HEPE can also be used as the active ingredient of the present invention.
[0026] The active ingredient of the present invention is fat-soluble and is present, for example, in an oil fraction prepared from a source organism. Typically, the composition containing the active ingredient of the present invention can be prepared as an oil fraction obtained by adding water to a raw material such as krill, grinding it, and then decomposing the protein components by enzymatic decomposition and centrifuging it. If necessary, it is also possible to produce a powdered composition containing the active ingredient of the present invention by drying the oil fraction prepared in this manner. Alternatively, the composition containing the active ingredient of the present invention can be produced as an oil fraction by separating a liquid fraction containing an oil fraction and a solid fraction, and then separating the liquid fraction containing the oil fraction obtained into an oil fraction and a water fraction. The oil fraction obtained in this manner can also be prepared as a solid component (e.g., powder) by drying it as necessary.
[0027] Alternatively, the composition containing the active ingredient of the present invention can be prepared as an organic solvent extract of the starting material (which may be crushed or ground if necessary). If necessary, the organic solvent extract thus prepared can be dried to produce a powdered composition containing the active ingredient of the present invention. Examples of solvents that can be used to prepare the composition containing the active ingredient of the present invention include, but are not limited to, ethyl alcohol, acetone, and hexane.
[0028] The compositions prepared by the above methods can also be further purified, for example by chromatography, before use in the present invention.
[0029] A representative method for preparing a composition containing the active ingredient of the present invention is to use the method described in JP 2019-178127 A, for example: The crushed krill suspended in water is enzymatically treated with protease derived from Aspergillus oryzae under pH 3-4 conditions to obtain an oil fraction, which is then dried. If necessary, adjust the pH using organic acids and / or carbonic acid. - Use citric acid as an organic acid if necessary. This is carried out by:
[0030] The starting material may be fresh or frozen (eg, unhydrated or hydrated frozen blocks stored at -50°C or below).
[0031] The starting materials are preferably crushed roughly using a meat chopper in a room temperature environment, for example, after the starting materials are kept at −10 to −3° C. (frozen starting materials are thawed to this temperature range), and then crushed using a mass colloider until they become pasty, in order to produce a composition containing an active ingredient of excellent quality.
[0032] The crushed starting material thus obtained is suspended in water and enzymatically treated with protease derived from Aspergillus oryzae under conditions of pH 3 to 4. The suspension of the crushed starting material in water may be performed, for example, by adding 0.3 to 0.7 parts by weight of water to 1 part by weight of the crushed starting material and stirring. The protease derived from Aspergillus oryzae may be at least one selected from acidic proteases, neutral proteases, and alkaline proteases derived from Aspergillus oryzae. Commercially available products include Kokurase P Granules (manufactured by Mitsubishi Chemical Foods Corporation), which is a mixed preparation of these, and Orientase OP (manufactured by HI Corporation) and Sumiteam FP (manufactured by Shin Nippon Chemical Industry Co., Ltd.), which are neutral protease preparations. For example, 0.001 to 0.03 parts by weight of the protease derived from Aspergillus oryzae is used for 1 part by weight of the crushed starting material, and the crushed starting material is enzymatically treated at its optimum temperature. The optimum temperature when using coclase P granules as the protease derived from koji mold is 50 to 55°C. The treatment time may be, for example, 30 minutes to 3 hours. The enzyme treatment of the crushed starting material using the protease derived from koji mold is performed under a condition of pH 3 to 4 in order to prevent lipids contained in the oil fraction obtained by the enzyme treatment of the crushed starting material from being decomposed by the lipid decomposition enzymes contained in the starting material itself. The pH can be adjusted using organic acids such as citric acid, lactic acid, acetic acid, glucuronic acid, ascorbic acid, etc., or carbonic acid, but it is preferable to adjust the pH using citric acid in order to ensure safety in producing pharmaceutical materials, food materials, etc. Citric acid can be used in an amount of 0.001 to 0.03 parts by weight per 1 part by weight of the aqueous suspension of the crushed starting material.
[0033] After the starting material is subjected to an enzyme treatment, the treatment liquid is heated to 70 to 75°C and incubated for 10 minutes to 1 hour to inactivate the protease, and then the oil fraction contained in the treatment liquid is recovered. The oil fraction can be recovered from the treatment liquid by, for example, centrifuging the treatment liquid using a dehydrating decanter at room temperature to separate it into a liquid fraction containing the oil fraction and a solid fraction, and then centrifuging the resulting liquid fraction containing the oil fraction using a concentrating decanter to separate it into an oil fraction and a water fraction.
[0034] Finally, the oil fraction separated from the water fraction is dried to obtain a composition containing the target active ingredient. The oil fraction may be dried, for example, by freeze drying, but can also be dried by spray drying or hot air drying. When the target composition containing the active ingredient is obtained as a solid, it may be pulverized into granules or powder.
[0035] A composition containing the active ingredient of the present invention produced by the above method contains, for example, 30 to 60% by weight of protein, 25 to 50% by weight of lipids, and 1 to 15% by weight of water, and is characterized in that it contains a large amount of 1-alkyl ether phospholipids (1 to 5% by weight of the composition containing the active ingredient of the present invention), which are known to be converted in the body into plasmalogens, which are believed to play an important role as lipids in maintaining cellular functions in mammals, but the proportions of other ingredients are not limited to these.
[0036] (Formulations containing the active ingredient of the present invention) The composition containing the active ingredient of the present invention prepared according to the description of this specification can be prepared in various formulations according to the desired form of use. For example, useful formulations include, but are not limited to, powders, capsules, and tablets. EXAMPLES
[0037] The production and effects of the composition of the present invention will be specifically described below based on examples, etc. However, the present invention is not limited to these.
[0038] Example 1: Preparation of a composition containing an active ingredient 10t of unhydrated frozen blocks (stored at -50℃) of Japanese sardines (Euphausia pacifica) caught in the Sanriku region were thawed at -5℃, roughly crushed using a commercially available meat chopper, and then crushed to a paste using a commercially available mass colloider. 15t of water suspension of crushed krill was prepared by adding 5t of pure water to 10t of the crushed krill, and stirring the mixture. 50kg of Kokurase P Granules (manufactured by Mitsubishi Chemical Foods Corporation), which is a protease derived from Aspergillus oryzae, was added to the suspension, and the pH of the liquid was adjusted to 3-4 by adding 150kg of citric acid, and the enzyme treatment was performed at 50℃. After 1 hour, the treatment liquid was heated to 70℃ and incubated for 30 minutes to inactivate the protease. After cooling the treatment liquid to room temperature, the treatment liquid was centrifuged using a commercially available dehydration decanter to separate 13t of liquid containing an oil fraction from the solids. Next, the obtained liquid containing the oil fraction was centrifuged using a commercially available concentrating decanter to separate 1.7 t of the oil fraction from the water fraction. The obtained oil fraction (red to pink oil-like substance) was freeze-dried, and the obtained solid was pulverized to obtain 374 g of the desired brown powdered isada component-containing composition. The isada component-containing composition thus obtained contained 44% by weight of protein, 28% by weight of lipid, and 10% by weight of water (the remainder being hydrocarbons and ash), and the lipid breakdown was 16.4% by weight of neutral lipid, 6.8% by weight of phosphatidylethanolamine, 40.8% by weight of phosphatidylcholine, 12.6% by weight of diacylglycerol, 16.7% by weight of free fatty acid, and 6.7% by weight of others, and the ratio of 1-alkyl ether type phospholipids in the isada component-containing composition was 2.7% by weight. The lipids contained in the Isada component-containing composition were analyzed by extracting lipids from 0.2 g of the sample (Isada component-containing composition) using the Bligh-Dyer method. The proportions of neutral lipids, phosphatidylethanolamine, phosphatidylcholine, diacylglycerol, and free fatty acids in the extracted lipids were measured by subjecting 1 μL of lipids dissolved in chloroform at a concentration of 10 mg / mL to a thin-layer chromatography-hydrogen flame ionization detector (Iatroscan: manufactured by LSI Medience Corporation).The thin-layer chromatograph was developed with chloroform / methanol / water (42:24:2.5) as the primary solvent, followed by hexane / diethyl ether (50:30) as the secondary solvent, to separate each lipid. The content of 1-alkyl ether phospholipids in the extracted lipids was quantified using high performance liquid chromatography (HPLC), and the percentage of 1-alkyl ether phospholipids in the sample was calculated. The high-performance liquid chromatograph used 30 μL of lipid solution dissolved in chloroform / methanol (2:1) at a concentration of 0.3 mg / mL as the analysis sample, and used a Lichrospher 100 Diol 250x4 (Agilent) column. Eluent A was hexane / 2-propanol / acetic acid (82:17:1) with 0.08% triethylamine, and eluent B was 2-propanol / water / acetic acid (85:14:1) with 0.08% triethylamine. The gradients were 95% eluent A / 5% eluent B (23 min gradient), 60% eluent A / 40% eluent B (4 min gradient), 15% eluent A / 85% eluent B (1 min hold followed by 4 min gradient), 95% eluent A / 5% eluent B. The solution was pumped at 5% (10 min hold) to separate 1-alkyl ether phospholipids, which were then detected using a light scattering detector (SOFTA). 1-hexadecenoyl-2-oleoyl-sn-glycero-3-phosphocoline (Funakoshi), a standard for 1-alkyl ether phospholipids, was used to create a calibration curve for quantification. Proteins were analyzed by the Kjeldahl method, and water content was analyzed by the heat drying method.
[0039] (Example 2: Measurement of the effect of improving sleep quality 1) The following tests were carried out using the composition containing the active ingredient of the present invention prepared in Example 1.
[0040] 1. Subject Selection The subjects of the clinical trial were healthy men and women aged 20 to 64 years. Subjects were selected based on a Pittsburgh Sleep Quality Index (PSQI-J) score of 6 or higher at the time of the pre-examination. However, the following were excluded based on the exclusion criteria: (1) those receiving drug therapy, dietary guidance, or exercise therapy; (2) those receiving treatment for sleep, stress, or fatigue; (3) those with diabetes, liver disease, kidney disease, heart disease, or other diseases that affect the secretion of adrenal cortical hormones, or other metabolic diseases, or those with a history of such diseases; (4) those with a history of mental illness, chronic fatigue syndrome, or insomnia; (5) those who have been diagnosed with or are suspected of having sleep apnea syndrome; (6) those with nocturnal frequency of urination (2 or more times); (7) those with diseases that require constant medication, those with serious diseases that require medication, or those with a history of such diseases; and (8) those who regularly use medicines, quasi-drugs, functional foods, or health foods that claim to improve fatigue, stress, or sleep. The clinical trial physician in charge, who specializes in neurosurgery, ultimately determined whether the subjects were suitable. Therefore, the subjects of the present invention were set as "healthy adult men and women who are temporarily dissatisfied with their sleep."
[0041] 2. Clinical Trials After obtaining consent, the volunteers were asked to take part in the study, and the SCR (short for screening) (screening items include background survey, height, weight, BMI, interview, vital signs, blood test, urine test, VAS questionnaire, OSA-MA, and POMS2) was administered. Two weeks before the start of intake and at week 0 of intake, VAS (short for Visual Analog Scale) questionnaire, OSA-MA, and POMS2 were administered. After 8 weeks of intake of the composition containing the active ingredient, the subjects were again administered the test (weight, BMI, interview, vital signs, blood test, urine test, VAS questionnaire, OSA-MA, and POMS2). The clinical trial was conducted as a randomized, double-blind, parallel-group comparative study using a placebo as a control. For 8 weeks from the start of intake, the subjects continued to take 3 tablets a day with water or lukewarm water.
[0042] 3.Statistical analysis 3.1. Definition of statistical analysis population The primary analysis was PPS: 1) FAS: A group of all cases excluding cases with missing data 2) PPS: A group of cases in which the study diet was in compliance, there were no significant protocol violations, and no missing data.
[0043] 3.1.1.Analysis exclusion criteria The per protocol population (PPS) was determined by excluding cases that met the following exclusion criteria: 1) Subjects who meet the exclusion criteria for the study subjects 2) Cases in which the intake rate of the test food was less than 80% 3) Patients who took health foods or supplements multiple times during the study period that may affect the study. 4) Cases in which the results of clinical tests performed during the study period were found to have significantly undermined the credibility of the study. 5) Cases in which significant deviations from the study protocol were observed 6) Other cases that the investigator judges to be inappropriate for exclusion for obvious reasons.
[0044] 3.2.Efficacy evaluation 3.2.1. Analysis set for efficacy evaluation Efficacy evaluation was performed in the per protocol population (PPS).
[0045] 3.2.2. Analysis of efficacy evaluation Efficacy evaluation items (primary and secondary) Between groups: The test food group and the control food group were compared at week 0 and week 8 after the start of intake. Sleep measurements were compared between the test food group and the control food group based on the average sleep quality every two weeks from two weeks before the start of intake to week 0, week 0 to week 2, week 2 to week 4, week 4 to week 6, and week 6 to week 8. Within group: Week 0 of intake was used as the baseline, and comparison was made after 8 weeks of intake. For sleep data, the baseline was taken from two weeks before the start of intake to week 0, and comparisons were made between week 0 and week 2, week 2 and week 4, week 4 and week 6, and week 6 and week 8.
[0046] 3.2.3.Analysis method The testing methods used to analyze the efficacy evaluation items were as shown in Table 1 below.
[0047] [Table 1]
[0048] 3.2.4. Outliers and missing values Because PPS analysis was used as the primary analysis, missing values were not included in the data. Outliers were not taken into account in the analysis.
[0049] 3.2.5. Display and significance level Statistical analysis was performed using two-sided tests, and the significance level was set at 5%. When the significance level was met, the P value was indicated in the figure. The probability of significance (P value) was displayed to three decimal places by truncating the calculated value to four decimal places.
[0050] 3.2.6. Software used Excel Statistics (BellCurve) was used to calculate basic statistics and analyze the data.
[0051] 4. Formulations and Intake Used in the Study The compositions of the formulations used in the tests are shown in Table 2 below.
[0052] [Table 2]
[0053] The results are shown below.
[0054] 5.Results 5.1. Sleep quality measurement (sleep state VAS, OSA-MA) (primary endpoint) <Intergroup comparison> - Sleep status VAS: Significant differences were confirmed in the actual measured values and changes after 8 weeks of intake. · OSA-MA: Significant differences were confirmed in the actual measured values and changes in factor I (morning sleepiness) and factor IV (fatigue recovery) after 8 weeks of intake. <Intragroup comparison> - Sleep status VAS: A significant difference was confirmed when comparing the test food group at 0 weeks and 8 weeks of ingestion. OSA-MA: Significant differences were confirmed in factor I (sleepiness upon waking), factor II (falling asleep and maintaining sleep), factor III (dreaming), factor IV (fatigue recovery), and factor V (sleep time) of the test food group when comparing 0 weeks of intake with 8 weeks of intake.
[0055] Significant differences were confirmed in factor II (sleep onset and sleep maintenance) and factor V (sleep duration) in the control food group when comparing 0 weeks and 8 weeks of ingestion. The analysis results for the primary endpoints are shown in Tables 3 and 4 below.
[0056] [Table 3]
[0057] [Table 4]
[0058] The results of the primary endpoints are shown in the table above.
[0059] 5.2.Sleep measurement (Fitbit), POMS2, (secondary endpoint) <Intergroup comparison> -Sleep measurement (Fitbit): A significant difference was confirmed in the average light sleep duration from 4 weeks to 6 weeks of ingestion. POMS2: Significant differences were confirmed in the actual measured values of AH (anger-hostility) and F (friendship) at week 0 of intake. <Intragroup comparison> ·Sleep measurement (Fitbit): [Test food group] Using 2 weeks before the start of intake as the baseline, from week 0, significant differences were confirmed in the time spent awake from week 6 to week 8, in the number of times awakened from week 0 to week 2, from week 4 to week 6, and from week 6 to week 8. [Control food group] Using 2 weeks before the start of intake as a baseline (week 0), significant differences were confirmed in the amount of time spent awake from week 6 to week 8, the number of times awake from week 6 to week 8, and REM sleep from week 0 to week 2. POMS2: Significant differences were confirmed in the CB (confusion-bewilderment), DD (depression-dejection), TA (tension-anxiety), and TMD scores of the test food groups when compared between 0 weeks and 8 weeks of intake. Significant differences were confirmed in the control food group's CB (confusion-bewilderment), FI (fatigue-lethargy), VA (vigor-vitality), F (friendship), and TMD scores when compared between 0 weeks and 8 weeks of intake.
[0060] The analysis results of the following evaluation items are shown in Tables 5 to 9 below.
[0061] [Table 5]
[0062] [Table 6]
[0063] [Table 7]
[0064] [Table 8]
[0065] [Table 9]
[0066] The results of the secondary endpoints are shown in the table above.
[0067] 6. Relationship between clinical trial results and functionality 6.1. An increase in the proportion of deep sleep and REM sleep in total sleep in healthy subjects who were temporarily dissatisfied with their sleep was used as an indicator of improved sleep quality.
[0068] As a result of the clinical trial, the amount of change in the total time of sleep stages (non-REM sleep (N1)) in the sleep EEG analysis at the 12th week was significantly shorter in the group taking the composition containing the active ingredient than in the group taking the placebo. In addition, the proportion of each sleep stage (non-REM sleep (N3)) and the proportion of each sleep stage (REM sleep (R)) were significantly greater in the group taking the composition containing the active ingredient than in the group taking the placebo. On the other hand, there was no difference in total sleep time between the group taking the composition containing the active ingredient and the group taking the placebo. From the above, the composition containing the active ingredient of the present invention has the effect of improving sleep quality by increasing deep sleep and REM sleep without changing the total sleep time.
[0069] 6.2. Relieving anxiety, tension and depression in subjects with temporary low vitality and energy, temporarily improving vitality and energy, and reducing daytime sleepiness The Ministry of Health, Labor and Welfare's "Sleep Guidelines for Health Promotion 2014" reports that sleep disorders and mental health are closely related. The most obvious manifestation of excessive tension, which is the main cause of mental health disorders, is a decrease in vitality (Ministry of Health, Labor and Welfare, Everyone's Mental Health General Site: What is Stress?) (National Institute of Occupational Safety and Health, Independent Administrative Institution, Research Report on Items Appropriate to Confirm as Symptoms and Disorders Related to Stress, October 2010). Therefore, a subgroup analysis was performed using the POMS2 Vitality-Energy (VA) scale. No adjustment for multiplicity was made. In POMS2, a score of 50 on the scale is defined as "average state" (Heuchert et al., POMS2 Japanese Version Manual, Kaneko Shobo, 2015), so a group with a VA of less than 50 was defined as having decreased vitality and energy. POMS2 and PSQI-J were analyzed in this group. As a result, in the group with POMS2 VA of less than 50, the scores of POMS2 depression-depression, tension-anxiety, vigor-vitality, and overall mood state were significantly improved in the group taking the composition containing the active ingredient compared to the group taking the placebo. Therefore, the composition containing the active ingredient of the present invention has the potential to improve negative mood states such as tension-anxiety and depression in people with temporary low vigor and vitality. Furthermore, in the group with POMS2 VA of less than 50, the score of daytime wakefulness on the PSQI-J was significantly improved in the group taking the composition containing the active ingredient compared to the group taking the placebo. The daytime wakefulness is composed of two questions that ask whether or not the subject feels excessive sleepiness while driving, eating, or engaging in social activities, and whether or not the subject has the motivation necessary to get things done. Therefore, by taking a composition containing the active ingredient, it is possible that it can reduce daytime sleepiness in people who have a tendency to temporarily lose their vitality and energy, improve the efficiency of daily tasks such as work and housework, and contribute to reducing microsleep (Hayashi Mitsuo, Physiological Mechanism of Drowsiness While Driving, Journal of the International Society for Traffic Safety, 2013;38:49-56) in situations where constant attention is required, such as while driving. From the above, it is believed that the composition containing the active ingredient of the present invention can relieve anxiety, tension, and depression in people who have a temporary loss of vitality and energy, and is useful for temporarily improving vitality and energy and reducing daytime sleepiness.
[0070] (Example 3: Measurement of the effect of improving sleep quality 2) The following tests were carried out using the composition containing the active ingredient of the present invention prepared in Example 1.
[0071] 1.Calculation method The time spent in bed (total sleep time, i.e., the time from going to bed to waking up) was set as 100, and the percentages of "sleep time," "time awake," "REM sleep," "light sleep," and "deep sleep" were calculated and expressed as "%." The amount of change from before the start of the test (2 weeks before and 1 week before) was calculated using the following formula: (Values for 1-2 weeks or 3-4 weeks) - (Before the start of the study) The average value and standard error were calculated.
[0072] In subjects aged 60-69 years, the proportion of light sleep decreased and the proportion of REM sleep and deep sleep increased at 3-4 weeks, 5-6 weeks, and 7-8 weeks.
[0073] 2.Results The results are shown in Tables 10 to 14 below.
[0074] [Table 10]
[0075] [Table 11]
[0076] [Table 12]
[0077] [Table 13]
[0078] [Table 14]
[0079] The composition provided by the present invention improved sleep quality, and demonstrated excellent effects, particularly in subjects in their 60s, such as a reduction in the proportion of light sleep and an increase in the proportion of REM sleep and deep sleep.
[0080] As described above, the present invention has been illustrated using the preferred embodiment of the present invention, but the present invention should not be interpreted as being limited to this embodiment. It is understood that the scope of the present invention should be interpreted only by the claims. It is understood that a person skilled in the art can implement an equivalent scope based on the description of the present invention and technical common sense from the description of the specific preferred embodiment of the present invention. It is understood that the patents, patent applications and literature cited in this specification should be incorporated by reference to this specification in the same manner as if the contents themselves were specifically described in this specification. [Industrial Applicability]
[0081] The composition provided by the present invention makes it possible to improve the quality of sleep.
Claims
1. A composition for improving sleep quality, comprising an oil component of an organism of the superorder Polypodidae, a solid component obtained by drying the oil component, an organic solvent extract of an organism of the superorder Polypodidae, a solid component obtained by drying the dried organic solvent extract, and a substance selected from the group consisting of 8-hydroxyeicosapentaenoic acid (8-HEPE).
2. The composition of claim 1 , wherein the organism of the superorder Euphausiidae is an organism of the order Euphausiidae.
3. 3. The composition of claim 2, wherein the Euphausiformes organism is selected from the group consisting of Euphausia pacifica, Euphausia superba, and combinations thereof.
4. The composition according to claim 3 , wherein the organism of the order Euphausiidae is Euphausia pacifica.
5. The composition according to claim 1, wherein the oil component is a treatment liquid obtained by enzymatically treating ground material of the organism suspended in an aqueous solution with a protease under conditions of pH 3 to 4.
6. The composition according to claim 5 , wherein the protease is a protease derived from Aspergillus oryzae.
7. The composition of claim 1 , wherein the solid component is a powder.
8. 2. The composition of claim 1, wherein the organic solvent extract is an extract prepared using a solvent selected from the group consisting of ethyl alcohol, acetone, and hexane.
9. 2. The composition of claim 1, wherein the improvement in sleep quality is selected from the group consisting of a decrease in the percentage of light sleep time relative to total sleep time, an increase in the percentage of deep sleep time relative to total sleep time, and combinations thereof.
10. The composition according to claim 1 , which is a dietary composition or a pharmaceutical composition.
Citation Information
Patent Citations
BRC.2007
